AtriCure, Inc. (NASDAQ:ATRC) will be discussing 2Q20 financial results with the investment community.on 28th July 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.atricure.com
Earnings Expectation
AtriCure, Inc. is reporting second quarter earnings results on Tuesday 28th July 2020, after market close. The consensus estimates from Thomson Reuters are loss of $ 0.57 per share from $ 35.95 million in revenue. For the full year, analysts predict revenues of $ 204.33 million, while looking forward to loss of $ 1.66 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 254.00 million ~ $ 261.00 million, where as bottomline are predicted in a range of $ -1.24 ~ $ -1.14 per share
Click Here For More Historical Outlooks Of AtriCure, Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
